News
CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today ...
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
The FDA's approval of the first CRISPR-Cas9–based gene therapy marked a major milestone in biomedicine, validating genome ...
There's a fresh push to edit the genes of human embryos to prevent diseases and enhance characteristics that parents value.
Currently, GenAns Biotech is conducting investigator-initiated trials for several gene therapies, including GA001 for ...
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB ...
Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs -- APOE program added to ...
A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.
Uppsala University Hospital-led investigators report that gene-edited donor islet cells survived 12 weeks inside a man with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results